Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^* Talarico Ernest III	2. Issuer Name and Ticker or Trading Symbol NEWLINK GENETICS CORP [ (NLNK) ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __ X __ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below)
(Last) (First) (Middle) C/O NEWLINK GENETICS CORPORATION, 2503 SOUTH LOOP DR., SUITE 5100	3. Date of Earliest Transaction (MM/DD/YYYY) 7/31/2019
(Street) AMES, IA 50010 (City) (State) (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _ X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

*Table II - Derivative Securities Beneficially Owned ( e.g.* , puts, calls, warrants, options, convertible securities)**
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)			11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$3.07	7/31/2019		D			23809	3/3/2011	3/2/2020	Common Stock	23809.0	⁽¹⁾	0	D
Stock Option (Right to Buy)	$1.77	7/31/2019		A		11905		⁽²⁾	7/31/2026	Common Stock	11905.0	⁽¹⁾	11905	D
Stock Option (Right to Buy)	$3.07	7/31/2019		D			23809	3/3/2010	3/2/2020	Common Stock	23809.0	⁽¹⁾	0	D
Stock Option (Right to Buy)	$1.77	7/31/2019		A		11905		⁽²⁾	7/31/2026	Common Stock	11905.0	⁽¹⁾	11905	D
Stock Option (Right to Buy)	$10.02	7/31/2019		D			11904	1/1/2012	12/8/2020	Common Stock	11904.0	⁽¹⁾	0	D
Stock Option (Right to Buy)	$1.77	7/31/2019		A		5952		⁽²⁾	7/31/2026	Common Stock	5952.0	⁽¹⁾	5952	D
Stock Option (Right to Buy)	$10.02	7/31/2019		D			2380	12/9/2011	12/8/2020	Common Stock	2380.0	⁽¹⁾	0	D
Stock Option (Right to Buy)	$1.77	7/31/2019		A		1190		⁽²⁾	7/31/2026	Common Stock	1190.0	⁽¹⁾	1190	D
Stock Option (Right to Buy)	$13.3	7/31/2019		D			11902	⁽³⁾	11/1/2022	Common Stock	11902.0	⁽⁴⁾	0	D
Stock Option (Right to Buy)	$1.77	7/31/2019		A		3968		⁽²⁾	7/31/2026	Common Stock	3968.0	⁽⁴⁾	3968	D
Stock Option (Right to Buy)	$14.71	7/31/2019		D			12000	⁽⁵⁾	5/8/2023	Common Stock	12000.0	⁽⁴⁾	0	D
Stock Option (Right to Buy)	$1.77	7/31/2019		A		4000		⁽²⁾	7/31/2026	Common Stock	4000.0	⁽⁴⁾	4000	D
Stock Option (Right to Buy)	$21.23	7/31/2019		D			15659	⁽⁵⁾	4/30/2024	Common Stock	15659.0	⁽⁴⁾	0	D
Stock Option (Right to Buy)	$1.77	7/31/2019		A		5220		⁽²⁾	7/31/2026	Common Stock	5220.0	⁽⁴⁾	5220	D
Stock Option (Right to Buy)	$44.6	7/31/2019		D			6349	⁽⁵⁾	4/29/2025	Common Stock	6349.0	⁽⁶⁾	0	D
Stock Option (Right to Buy)	$1.77	7/31/2019		A		1588		⁽²⁾	7/31/2026	Common Stock	1588.0	⁽⁶⁾	1588	D
Stock Option (Right to Buy)	$10.78	7/31/2019		D			17774	⁽⁵⁾	8/8/2026	Common Stock	17774.0	⁽¹⁾	0	D
Stock Option (Right to Buy)	$1.77	7/31/2019		A		8887		⁽²⁾	7/31/2026	Common Stock	8887.0	⁽¹⁾	8887	D
Stock Option (Right to Buy)	$10.78	7/31/2019		D			4782	⁽⁵⁾	8/8/2026	Common Stock	4782.0	⁽¹⁾	0	D
Stock Option (Right to Buy)	$1.77	7/31/2019		A		2391		⁽²⁾	7/31/2026	Common Stock	2391.0	⁽¹⁾	2391	D
Stock Option (Right to Buy)	$17.42	7/31/2019		D			13309	⁽⁵⁾	5/11/2027	Common Stock	13309.0	⁽⁴⁾	0	D
Stock Option (Right to Buy)	$1.77	7/31/2019		A		4437		⁽²⁾	7/31/2026	Common Stock	4437.0	⁽⁴⁾	4437	D
Stock Option (Right to Buy)	$5.33	7/31/2019		D			27777	⁽⁵⁾	5/22/2028	Common Stock	27777.0	⁽¹⁾	0	D
Stock Option (Right to Buy)	$1.77	7/31/2019		A		13889		⁽²⁾	7/31/2026	Common Stock	13889.0	⁽¹⁾	13889	D

Explanation of Responses:
(1)	On July 31, 2019, the issuer cancelled this option grant pursuant to the issuer's option exchange program. In exchange, for every two cancelled options, the reporting person received a replacement option having an exercise price of $1.77 per share.
(2)	The option vests as to 50% on the first anniversary of grant date and the remaining 50% on the second anniversary of grant date.
(3)	The option provided that 50% of the option vested on November 2, 2013 and the remaining 50% of such option vested in equal monthly installments over the next 12 months, provided (i) that the option shall vest in full on the date of the Annual Meeting held two years after the date of grant and (ii) that at the relevant vesting dates the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan.
(4)	On July 31, 2019, the issuer cancelled this option grant pursuant to the issuer's option exchange program. In exchange, for every three cancelled options, the reporting person received a replacement option having an exercise price of $1.77 per share.
(5)	The option provided that one hundred percent (100%) of the shares would vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the first Annual Meeting following the date of grant, in each case subject to the Reporting Person's continuous service as of such date.
(6)	On July 31, 2019, the issuer cancelled this option grant pursuant to the issuer's option exchange program. In exchange, for every four cancelled options, the reporting person received a replacement option having an exercise price of $1.77 per share.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Talarico Ernest III C/O NEWLINK GENETICS CORPORATION 2503 SOUTH LOOP DR., SUITE 5100 AMES, IA 50010	X

Signatures
/s/ Ryan Trytten, attorney-in-fact		8/2/2019
^** Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.